{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:42:45Z","timestamp":1787240565698,"version":"build-2736575974"},"reference-count":29,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cancer Control"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The burden of prostate cancer (PCa) is disproportionately concentrated in low- and middle-income countries (LMICs). Abiraterone and enzalutamide have improved survival rates and quality of life for men with PCa. However, cost constraints limit access to these medications due to limited insurance coverage and out-of-pocket payments. The survey assessed the current practices and opinions of Nigerian clinical oncologists and urologists regarding the use of low dose abiraterone and enzalutamide for the management of metastatic PCa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This survey consisted of twenty multiple-choice questions, distributed via Google Forms to urologists and oncologists in Nigeria from August to November 2024. It examined current practices, awareness of effective dose reduction strategies, and opinions on their cost-effectiveness. The collected data were entered into Microsoft Excel, and responses were presented using tables and charts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 104 respondents completed the survey. Among them, 37 (36%) reported that 61%\u201380% of their patients initially presented with advanced PCa. Additionally, 55 respondents (53%) were unaware of studies and guidelines regarding low-dose abiraterone. Furthermore, 66% of clinicians indicated that fewer than 20% of their patients could afford abiraterone, and 91 (87.5%) noted that few could afford enzalutamide. Moreover, 92 (89%) respondents believed that low-dose abiraterone would improve compliance, while 76% felt that reducing the enzalutamide dose would also enhance compliance and decrease patient costs. Sixty percent (58%) of respondents were willing to switch to low-dose abiraterone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The survey revealed limited awareness of landmark studies on dose-reduction strategies for abiraterone and enzalutamide. These strategies have the potential to enhance affordability and compliance in the management of advanced PCa in Nigeria.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10732748251390022","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:31:20Z","timestamp":1762000280000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Strategies for Improving Access to Effective Prostate Cancer Medications (Abiraterone and Enzalutamide) in Low- and Middle-Income Countries (LMICs): A Survey Among Nigerian Health Professionals"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9219-9069","authenticated-orcid":false,"given":"Omolara","family":"Fatiregun","sequence":"first","affiliation":[{"name":"Lagos State University College of Medicine"},{"name":"Lagos State University Teaching Hospital"},{"name":"University of Toronto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onyeanunam","family":"Ekeke","sequence":"additional","affiliation":[{"name":"University of Port Harcourt Teaching Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2141-6537","authenticated-orcid":false,"given":"Egbuchilem","family":"Chisor-Wabali","sequence":"additional","affiliation":[{"name":"Rivers State University Teaching Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Raphael","sequence":"additional","affiliation":[{"name":"University of Port Harcourt Teaching Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Okpani","sequence":"additional","affiliation":[{"name":"University of Port Harcourt Teaching Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kufre","family":"Udoh","sequence":"additional","affiliation":[{"name":"University of Port Harcourt Teaching Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Okigbeye","family":"Danagogo","sequence":"additional","affiliation":[{"name":"Rivers State University Teaching Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oto-Obong","family":"Peters","sequence":"additional","affiliation":[{"name":"University of Uyo Teaching Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olusegun","family":"Biyi-Olutunde","sequence":"additional","affiliation":[{"name":"University of Port Harcourt Teaching Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3775-0492","authenticated-orcid":false,"given":"Nwamaka","family":"Lasebikan","sequence":"additional","affiliation":[{"name":"National Institute for Cancer Research and Treatment"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Temitope","family":"Olatunji","sequence":"additional","affiliation":[{"name":"Lagos State University College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omisanjo","family":"Olufunmilade","sequence":"additional","affiliation":[{"name":"Lagos State University College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuerowo","family":"Odunayo","sequence":"additional","affiliation":[{"name":"Lagos State University College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abolarinwa","family":"Abimbola","sequence":"additional","affiliation":[{"name":"Lagos State University College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basit","family":"Balogun","sequence":"additional","affiliation":[{"name":"Cancer Explore Foundation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4135-6524","authenticated-orcid":false,"given":"Boluwatife","family":"Borisade","sequence":"additional","affiliation":[{"name":"Cancer Explore Foundation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"James","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research"},{"name":"The Royal Marsden Hospital NHS Foundation Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Tannock","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre"},{"name":"University of Toronto"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,11]]},"reference":[{"issue":"8","key":"e_1_3_5_2_2","first-page":"711","article-title":"The precise role of ethnicity and family history on aggressive prostate cancer: a review analysis","volume":"64","author":"Powell IJ","year":"2011","unstructured":"Powell IJ. The precise role of ethnicity and family history on aggressive prostate cancer: a review analysis. Arch Esp Urol. 2011;64(8):711-719.","journal-title":"Arch Esp Urol"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-021-01672-y"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JGO.2016.008862"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-20-1005"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-017-0228-0"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00720-8"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00651-2"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2189"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014618"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60172-9"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.628744"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00700-7"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.4381"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e19315"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JGO.19.00341"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1888704"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00642"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/GO.22.00017"},{"key":"e_1_3_5_21_2","unstructured":"Society of oncology and cancer research of Nigeria (SOCRON). Available from: https:\/\/socron.net\/about-us. Accessed September 9 2025."},{"key":"e_1_3_5_22_2","volume-title":"National Cancer Control Plan (NCCP) 2018\u20132022","author":"Federal Government of Nigeria","year":"2017","unstructured":"Federal Government of Nigeria. National Cancer Control Plan (NCCP) 2018\u20132022. Federal ministry of health; 2017. Available from: https:\/\/www.iccp-portal.org\/plans\/nigeria. Accessed September 8, 2025."},{"issue":"1","key":"e_1_3_5_23_2","doi-asserted-by":"crossref","first-page":"e000198","DOI":"10.1136\/bmjonc-2023-000198","article-title":"Comparison of standard-dose and reduced-dose treatment of metastatic prostate cancer with enzalutamide, apalutamide, or darolutamide: a rapid review","volume":"3","author":"Bromley HL","year":"2024","unstructured":"Bromley HL, Varughese M, Gilbert DC, et al. Comparison of standard-dose and reduced-dose treatment of metastatic prostate cancer with enzalutamide, apalutamide, or darolutamide: a rapid review. BMJ Oncol. 2024;3(1):e000198.","journal-title":"BMJ Oncol"},{"key":"e_1_3_5_24_2","unstructured":"Generic Oncology Drugs Market Report 2024-2032. Bioprocess analyzers market scar treatment market generic oncology drugs market. 2024. [cited 2025 May 25]. Available from: https:\/\/portals.gminsights.com\/gmidrive\/sales\/Secure\/access\/.S@Vhpw==?leadid=482888"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-023-00562-w"},{"key":"e_1_3_5_26_2","unstructured":"Nigeria Institute for Cancer Research and Treatment. NICRAT-STRATEGIC-PLAN- cervical Cancer-2023-2027."},{"key":"e_1_3_5_27_2","unstructured":"Janssen CarePath. ZYTIGA. Patient Assistance\/ZYTIGA (abiraterone acetate). Patient and cost support program information. Available from: https:\/\/www.zytiga.com\/starting-zytiga\/patient-and-cost-support\/. Accessed September 8 2025."},{"key":"e_1_3_5_28_2","unstructured":"Pharma A. Astellas patient assistance Program\/XTANDI (enzalutamide). Available from: https:\/\/www.astellaspharmasupportsolutions.com\/products\/xtandi\/patient_assistance\/. Accessed September 8 2025."},{"key":"e_1_3_5_29_2","volume-title":"CHAI and ACS Announce Agreement to Expand Cancer Access Partnership","author":"Clinton Health Access Initiative & American Cancer Society","unstructured":"Clinton Health Access Initiative & American Cancer Society. CHAI and ACS Announce Agreement to Expand Cancer Access Partnership. Press Release. Available from: https:\/\/www.clintonhealthaccess.org\/news\/chai-and-acs-announce-agreement-to-expand-cancer-access-partnership\/. Accessed 8 September 2025."},{"key":"e_1_3_5_30_2","volume-title":"NHIA-Roche Oncology Cost-Sharing Initiative","author":"National Health Insurance Authority & Roche Nigeria","year":"2025","unstructured":"National Health Insurance Authority & Roche Nigeria. NHIA-Roche Oncology Cost-Sharing Initiative. 2025. Available from: https:\/\/punchng.com\/nhia-partners-roche-to-slash-cancer-treatment-costs-by-80\/. Accessed September 8, 2025."}],"container-title":["Cancer Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10732748251390022","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10732748251390022","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10732748251390022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:24:09Z","timestamp":1777386249000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10732748251390022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":29,"alternative-id":["10.1177\/10732748251390022"],"URL":"https:\/\/doi.org\/10.1177\/10732748251390022","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/10732748251390022\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748251390022\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748251390022\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748251390022\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748251390022\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748251390022\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748251390022\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748251390022\/v2\/review1","asserted-by":"object"}]},"ISSN":["1073-2748","1526-2359"],"issn-type":[{"value":"1073-2748","type":"print"},{"value":"1526-2359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"article-number":"10732748251390022"}}